Glucolipotoxicity initiates pancreatic β-cell death through TNFR5/CD40-mediated STAT1 and NF-κB activation

[1]  H. Woodrow,et al.  : A Review of the , 2018 .

[2]  P. Marchetti.  Islet inflammation in type 2 diabetes , 2016, Diabetologia.

[3]  D. Mears,et al.  Glucose-Dependent Insulin Secretion in Pancreatic β-Cell Islets from Male Rats Requires Ca2+ Release via ROS-Stimulated Ryanodine Receptors , 2015, PloS one.

[4]  A. Pedersen,et al.  Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials , 2014, Immunopharmacology and immunotoxicology.

[5]  U. Boggi,et al.  Are we overestimating the loss of beta cells in type 2 diabetes? , 2014, Diabetologia.

[6]  D. Kowalski,et al.  A Phase 1, Randomized Ascending Single‐Dose Study of Antagonist Anti‐Human CD40 ASKP1240 in Healthy Subjects , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  D. van der Kooy,et al.  The adult mammalian pancreas contains separate precursors of pancreatic and neural crest developmental origins. , 2013, Stem cells and development.

[8]  U. Boggi,et al.  Microarray analysis of isolated human islet transcriptome in type 2 diabetes and the role of the ubiquitin–proteasome system in pancreatic beta cell dysfunction , 2013, Molecular and Cellular Endocrinology.

[9]  T. Mandrup-Poulsen,et al.  Transcriptional and translational regulation of cytokine signaling in inflammatory β-cell dysfunction and apoptosis. , 2012, Archives of biochemistry and biophysics.

[10]  E. A. Ismail,et al.  Soluble CD40L in children and adolescents with type 1 diabetes: relation to microvascular complications and glycemic control , 2012, Pediatric diabetes.

[11]  S. Jagannath,et al.  A phase 1 study of lucatumumab, a fully human anti‐CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma , 2012, British journal of haematology.

[12]  M. Inoue,et al.  Insulin resistance and cancer: epidemiological evidence. , 2012, Endocrine-related cancer.

[13]  J. Byrd,et al.  Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia , 2012, Leukemia & lymphoma.

[14]  M. Ezzati,et al.  National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants , 2011, The Lancet.

[15]  T. Ørntoft,et al.  STAT1 Is a Master Regulator of Pancreatic β-Cell Apoptosis and Islet Inflammation* , 2010, The Journal of Biological Chemistry.

[16]  M. Inoue,et al.  Insulin resistance and cancer: Epidemiological evidence , 2010, Cancer science.

[17]  D. Leroith,et al.  Type 2 diabetes and cancer: what is the connection? , 2010, The Mount Sinai journal of medicine, New York.

[18]  L. Zitvogel,et al.  Pyroptosis – a cell death modality of its kind? , 2010, European journal of immunology.

[19]  J. Börgel,et al.  Influence of glycaemic control on platelet bound CD40–CD40L system, P‐selectin and soluble CD40 ligand in Type 2 diabetes , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[20]  G. Hitman,et al.  Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. , 2009, Arthritis and rheumatism.

[21]  Lincoln Stein,et al.  Reactome knowledgebase of human biological pathways and processes , 2008, Nucleic Acids Res..

[22]  C. Ricordi,et al.  CD40 activation in human pancreatic islets and ductal cells , 2008, Diabetologia.

[23]  H. Ellingsgaard,et al.  Increased Number of Islet-Associated Macrophages in Type 2 Diabetes , 2007, Diabetes.

[24]  M. Andersen,et al.  Reactive Oxygen Species as a Signal in Glucose-Stimulated Insulin Secretion , 2007, Diabetes.

[25]  G. Hitman,et al.  Effect of glucolipotoxicity and rosiglitazone upon insulin secretion. , 2007, Biochemical and biophysical research communications.

[26]  T. Wekerle,et al.  New approaches to prevent transplant rejection: Co-stimulation blockers anti-CD40L and CTLA4Ig , 2006 .

[27]  C. Murphy.  Using whole-genome transcriptional analyses to identify molecular mechanisms of aging , 2006 .

[28]  V. Mohan,et al.  Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome--the Chennai Urban Rural Epidemiology Study. , 2006, Metabolism: clinical and experimental.

[29]  N. Munshi,et al.  Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. , 2005, Cancer research.

[30]  D. Klein,et al.  A functional CD40 receptor is expressed in pancreatic beta cells , 2005, Diabetologia.

[31]  Christopher J. Rhodes,et al.  Type 2 Diabetes-a Matter of ß-Cell Life and Death? , 2005, Science.

[32]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[33]  D. Boumpas,et al.  Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients , 2004, Lupus.

[34]  G. Illei,et al.  A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. , 2003, Arthritis and rheumatism.

[35]  D. Ron,et al.  Endoplasmic reticulum stress and the development of diabetes: a review. , 2002, Diabetes.

[36]  H. Joller-jemelka,et al.  Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. , 2002, The Journal of clinical investigation.

[37]  Christophe Benoist,et al.  β-Cell death during progression to diabetes , 2001, Nature.

[38]  C. Wollheim,et al.  Mitochondrial glutamate acts as a messenger in glucose-induced insulin exocytosis , 1999, Nature.

[39]  P. Maechler,et al.  Free radical modulation of insulin release in INS-1 cells exposed to alloxan. , 1999, Biochemical pharmacology.

[40]  P. Behn,et al.  A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome) , 1998, Nature Genetics.

[41]  S. Lenzen,et al.  Relation Between Antioxidant Enzyme Gene Expression and Antioxidative Defense Status of Insulin-Producing Cells , 1997, Diabetes.

[42]  G. Hitman,et al.  Differential cytokine secretion resulting from p65 and c-Rel NF-kappaB subunit signaling in peripheral blood mononuclear cells of TNFR-associated periodic fever syndrome patients , 2011 .

[43]  G. Hitman,et al.  Differential cytokine secretion results from p65 and c-Rel NF-κB subunit signaling in peripheral blood mononuclear cells of TNF receptor-associated periodic syndrome patients. , 2011, Cellular immunology.

[44]  H. Ellingsgaard,et al.  Islet Inflammation Impairs the Pancreatic β-Cell in Type 2 Diabetes , 2009 .

[45]  G. Hitman,et al.  Proinflammatory action of the antiinflammatory drug infliximab in TNF-receptor associated periodic syndrome , 2009 .

[46]  G. Hitman,et al.  Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome. , 2008, Arthritis and rheumatism.

[47]  C. Rhodes.  Type 2 diabetes-a matter of beta-cell life and death? , 2005, Science.

[48]  C Benoist,et al.  beta-Cell death during progression to diabetes. , 2001, Nature.